Oncology Nursing News Top Stories: May 2022

Article

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from May 2022.

Each month, we take a look back at the most popular Oncology Nursing News® stories.

Topics from May 2022 include evolving treatments with endocrine therapy, nurse perspectives on reducing central line infections, and the role of the death doula in providing end-of-life care for patients with cancer. Other top stories included conference coverage from the 2022 Tandem Meetings Transplantation & Cellular Therapy Meetings, the 2022 European Society for Medical Oncology Breast Cancer Congress, and the 47th Annual Oncology Nursing Society Congress.

5. Loyda Braithwaite Discusses Evolving Treatment Options in HR+ Breast Cancer

In this episode of The Vitals, Loyda E. Braithwaite, MSN, RN, AGPCNP-BC, AOCNP, an oncology nurse practitioner at the University of Wisconsin Carbone Cancer Center, highlights nursing considerations in prescribing and administering endocrine therapy to patients with hormone receptor–positive breast cancer.

4. Oncology Nurses Drastically Reduce Central Line Infection Incidences Through Peer-to-Peer Observation Strategy

Oncology nurses at the 2022 Tandem Meetings Transplantation & Cellular Therapy Meetings of ACTCT and CIBMTR shared how a peer-to-peer observation and validation tool helped decrease central line-associated bloodstream infections by 68%.

3. Trastuzumab Deruxtecan Continues to Elicit Responses in HER2+ Breast Cancer With Active Brain Metastases

Most patients with HER2-positive breast cancer and brain metastases enrolled in the phase 2 TUXEDO-1 trial (NCT04752059) derived clinical benefit from treatment with fam-trastuzumab deruxtecan-nxki (Enhertu), according to data presented at the European Society for Medical Oncology Breast Cancer Congress 2022.

2. Time-Limited Ublituximab/Umbralisib Plus Ibrutinib Shows Efficacy, Tolerability in CLL

The addition of ublituximab and umbralisib (Ukoniq) to ibrutinib (Imbruvica) demonstrated a 77% undetectable minimal residual disease rate in patients with chronic lymphocytic leukemia, according to phase 2 results presented at the 47th Annual Oncology Nursing Society Congress.

1. Incorporating a Death Doula into the Oncology Care Team

The death doula is a unique role that can help oncology care teams improve the quality of end-of-life care delivered to patients. In this conference highlight from the 47th Annual Oncology Nursing Society Congress, Lorraine Holtsland, PhD, RN, CHPN, outlines how the oncology nurse and death doula might work together under the square of care framework.

To stay on top of all the latest news and features subscribe to our newsletter. As always, thank you for reading.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.